Xencor (XNCR) Shares Outstanding (2013 - 2026)
Xencor (XNCR) posted quarterly Shares Outstanding (Entity) of $74.1 million for Q1 2026, up 4.12% year-over-year from $71.1 million in Q1 2025, and up 3.05% quarter-over-quarter from $71.9 million in Q4 2025.
Analysis
Xencor (XNCR) Shares Outstanding (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Shares Outstanding (Entity) for 14 consecutive years, with $74.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 4.12% year-over-year to $74.1 million; the TTM figure through Mar 2026 stood at $74.1 million (up 4.12% YoY), while the FY2025 annual figure was $71.9 million, up 2.3% from the prior year.
- Shares Outstanding (Entity) rose to $74.1 million in Q1 2026 per XNCR's latest filing, from $71.9 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $74.1 million in Q1 2026 and bottomed at $59.5 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $65.0 million across 5 years, with a median of $61.6 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) increased 1.08% — and 2025, when it climbed 15.43%.
- Xencor's Shares Outstanding (Entity) stood at $60.0 million in 2022, then grew by 1.67% to $61.0 million in 2023, then rose by 15.18% to $70.3 million in 2024, then advanced by 2.3% to $71.9 million in 2025, then gained by 3.05% to $74.1 million in 2026.
- Business Quant data shows XNCR's Shares Outstanding (Entity) at $74.1 million in Q1 2026, $71.9 million in Q4 2025, and $71.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 75.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.86 Mn |
| Mar 31, 2026 | 75.25 Mn |
| Dec 31, 2025 | 74.24 Mn |
| Sep 30, 2025 | 74.41 Mn |
| Jun 30, 2025 | 74.28 Mn |
| Mar 31, 2025 | 73.67 Mn |
| Dec 31, 2024 | 65.04 Mn |
| Sep 30, 2024 | 64.02 Mn |
| Jun 30, 2024 | 61.68 Mn |
| Mar 31, 2024 | 61.21 Mn |
| Dec 31, 2023 | 60.50 Mn |
| Sep 30, 2023 | 60.62 Mn |
| Jun 30, 2023 | 59.81 Mn |
| Mar 31, 2023 | 59.77 Mn |
| Dec 31, 2022 | 59.65 Mn |
| Sep 30, 2022 | 59.72 Mn |
| Jun 30, 2022 | 59.57 Mn |
| Mar 31, 2022 | 59.41 Mn |
| Dec 31, 2021 | 58.38 Mn |
| Sep 30, 2021 | 58.35 Mn |